ADAPTIR™ and ADAPTIR-FLEX™ Therapeutic Canididate Portfolio

Product/ Candidate
Targets
Technology Potential Indications Pre-Clinical Clinical Development Stage Marketed Milestones/Highlights
Phase I Phase II Phase III
APVO436

CD3/CD123

Redirected T-Cell Cytotoxicity (RTCC) AML/MDS (R/R) Phase 1/1b study ongoing; 2 CR reported in cohort 6
APVO436

CD3/CD123

Redirected
T-Cell 
Cytotoxicity
AML front-line setting Selected for inclusion in groundbreaking ‘BEAT AML® Master Clinical Trial’ spearheaded by LLS
ALG.APV-527*

4-1BB/5T4

T-Cell Co-Stimulation Multiple Solid Tumors Advancing into clinical development with Alligator Bioscience in 2021
APVO603

4-1BB/OX40

Dual T-Cell Co-stimulation Multiple Solid Tumors Unique asset for use in multiple solid tumors; Advancing leading candidate
APVO442

PSMA/CD3

Redirected
T-Cell 
Cytotoxicity
CRPC Low affinity CD3 Advancing lead candidate
Multiple Candidates Bispecific RTCC and New MOA Hematologic and Solid Tumors Advancing new candidates that modulate the immune system

* Partnered with Alligator Bioscience